Explanatory Note
This Amendment No. 5 (this “Amendment”) amends and supplements the Schedule 13D filed on January 8, 2019, and as amended on April 26, 2019, July 12, 2019, July 16, 2019, and August 26, 2019 (as amended, the “Schedule 13D”), by the Reporting Persons relating to the common stock, par value $0.001 per share (the “Common Stock”), of Liberated Syndication, Inc. (the “Issuer”). Information reported in the Schedule 13D remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Schedule 13D.
Item 2. | Identity and Background |
Item 2 is amended to add the following:
In connection with the Settlement Agreement (as defined in Item 4), Michael Cricenti, Simeon McMillan, Adam Pincus and Bradly M. Tirpak are no longer members of a “group” and will cease to be Reporting Persons immediately after the filing of this Amendment. The remaining Reporting Persons will continue filing statements on Schedule 13D with respect to their beneficial ownership of securities of the Issuer to the extent required by applicable law. Each of the remaining Reporting Persons is party to the Joint Filing Agreement, as further described in Item 4.
Item 3. | Source and Amount of Funds or Other Consideration |
Item 3 is amended and restated as follows:
The shares of Common Stock purchased by Camac Fund were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 1,955,519 shares of Common Stock beneficially owned by Camac Fund is approximately $2,997,026.41, including brokerage commissions. The aggregate purchase price of the 63,385 shares of Common Stock beneficially owned by Mr. McMillan is approximately $94,242, excluding broker commissions.
Item 4. | Purpose of Transaction |
Item 4 is amended to add the following:
On October 4, 2019, the Issuer, Camac Fund and certain other parties entered into a Settlement Agreement (the “Settlement Agreement”).
Pursuant to the Settlement Agreement:
| • | | the Reporting Persons withdrew their (1) request to call a special meeting of stockholders of the Issuer; and (2) nomination of director candidates and business proposals in connection with the 2019 Annual Meeting; |
| • | | the Board is splitting the roles of Chairman of the Board and Chief Executive Officer, and the Issuer’s existing Chairman of the Board has resigned from that position (but not as a director); |
| • | | the Issuer appointed Messrs. Shahinian and Tirpak to the Board; |
| • | | the Issuer and Camac Fund will engage in good faith discussions to identify a mutually acceptable new independent director to join the Board (the “New Independent Director”), and if the New Independent Director joins the Board, then one of the Issuer’s legacy independent directors will resign from the Board; |
| • | | Mr. Shahinian will join the Board’s compensation committee and will serve as its chairman; |
| • | | Mr. Tirpak has been appointed to the Board’s audit committee; |
| • | | the Issuer will form a strategic review committee to make recommendations with respect to the strategic direction of the Issuer, and Mr. Shahinian will chair that committee; |
| • | | the Board will consist of no more than six members prior to the Issuer’s annual meeting of stockholders for fiscal year 2020 (the “2021 Annual Meeting”); |
| • | | the Issuer will cancel equity awards previously granted to its Chief Executive Officer and Chief Financial Officer representing an aggregate of 300,000 restricted shares (150,000 held by each of them), the vesting conditions with respect to which relate to the achievement by the Issuer of a an uplisting on The Nasdaq Stock Market; |
| • | | in connection with the Issuer’s annual meeting of stockholders for fiscal year 2019 (the “2020 Annual Meeting”), a new independent director will be included on the Board’s slate of director nominees in lieu of one of the Issuer’s legacy independent directors; |
| • | | if the Board nominates Messrs. Shahinian and Tirpak for election at the 2020 Annual Meeting, then Camac Fund will appear in person or by proxy at the 2020 Annual Meeting and vote its shares of Common Stock in favor of the Board’s director slate and the ratification of the Issuer’s auditor; |
| • | | the Issuer will hold the 2020 Annual Meeting no later than September 15, 2020, and the 2021 Annual Meeting no later than September 15, 2021; |
| • | | Camac Fund and Mr. Shahinian agreed to customary standstill restrictions lasting until September 1, 2020 (or earlier if the Board does not nominate Messrs. Shahinian and Tirpak for election at the 2020 Annual Meeting), including not (1) acquiring any voting securities (or voting rights decoupled from the underlying securities) of the Issuer in excess of 22% of the then-outstanding Common Stock (on a net long basis); (2) nominating or publicly recommending any person for election to the Board; (3) soliciting proxies; or (4) participating in the calling of a special meeting of the Issuer’s stockholders; |
| • | | Camac Fund will dismiss with prejudice the Verified Complaint and Alternative Petition for Writ of Mandamus/Prohibition regarding Camac Fund’s request to inspect certain books and records maintained by the Issuer filed by Camac Fund on July 15, 2019, in the District Court for Clark County, Nevada, Case No. A-19-798511-B; and |
| • | | the Issuer will reimburse Camac Fund for up to $600,000 of its expenses. |
The foregoing description of the Settlement Agreement is not complete and is qualified in its entirety by reference to the Settlement Agreement, which is attached as Exhibit 6 and is incorporated into this Item 4 by reference.
On October 4, 2019, the Issuer issued a press release concerning the Settlement Agreement. The press release is attached as Exhibit 7 and is incorporated into this Item 4 by reference.
On October 7, 2019, the applicable Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons who will remain Reporting Persons subsequent to this Amendment agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law. A copy of this agreement is attached as Exhibit 8 and is incorporated in this Item 4 by reference.
Item 5. | Interest in Securities of the Issuer |
Item 5 is amended and restated as follows:
(a) and (b) The responses of the Reporting Persons to rows 7, 8, 9, 10, 11 and 13 on the cover pages of this Amendment are incorporated by reference. As of 4:00 p.m., Eastern time, on October 7, 2019, (1) Camac Fund beneficially owned 1,955,519 shares of Common Stock, representing approximately 6.7% of the outstanding shares of Common Stock; (2) Mr. McMillan beneficially owned 63,385 shares of Common Stock, representing approximately 0.2% of the outstanding shares of Common Stock; and (3) no other Reporting Person beneficially owned shares of Common Stock.
Camac Capital, as the general partner of Camac Fund, may be deemed to have the power to direct the voting and disposition of the shares of Common Stock beneficially owned by Camac Fund, and may be deemed to be the indirect beneficial owner of such shares. Camac Capital disclaims beneficial ownership of such shares for all other purposes.
Camac Partners, as the investment manager of Camac Fund, may be deemed to have the power to direct the voting and disposition of the shares of Common Stock beneficially owned by Camac Fund, and may be deemed to be the indirect beneficial owner of such shares. Camac Partners disclaims beneficial ownership of such shares for all other purposes.
Page 9